Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon
Images coronary calcium imaging by optical coherence tomography (OCT) and high-definition intravascular ultrasound (IVUS).

OCT-guided PCI improves survival after life-threatening heart attacks

Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 

healthcare value value-based care money dollar

Medical device startup exits stealth mode to name CEO, announce $21M in funding

Jupiter Endovascular, a new subsidiary of Neptune Medical, aims to "bring the precision and control of direct surgical access to catheter-based interventions.”  

Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S

LAAO with Watchman FLX associated with positive 1-year outcomes, real-world data confirm

Researchers hoped to gain a better understanding of the device's real-world impact by reviewing registry data from more than 97,000 U.S. patients. Overall, the Watchman FLX was linked to positive data and limited adverse events one year after treatment. 

Treating mitral regurgitation with transcatheter mitral edge-to-edge repair (TEER) using the MitraClip device is associated with a low risk of cerebrovascular accidents (CVAs) such as stroke and transient ischemic attack (TIA), according to new data published in The American Journal of Cardiology.[1]

TEER with Abbott’s MitraClip linked to low stroke risk, new study confirms

Treating severe MR with the popular device does not appear to increase a patient's risk of stroke or transient ischemic attack. When patients present with AFib, however, care teams may want to make certain adjustments to optimize outcomes. 

Boston Scientific's Sentinel Cerebral Protection System during a TAVR procedure

Cerebral protection during TAVR linked to lower risk of major stroke, other key benefits

Using a cerebral protection device during TAVR was associated with lower readmission rates, shorter hospital stays—and, yes, a lower risk of patients suffering a major stroke. A team of specialists with Cleveland Clinic shared their new findings in the Journal of the American Heart Association.

doctor looking at CLTI patient's leg

FDA clears medical device company’s full line of vascular testing systems

The newly cleared devices are all designed to detect signs of PAD and/or PVD early enough that limb amputation is not required. 

stroke brain dementia alzheimer's puzzle mental health

Stroke after TAVR in AFib patients: Key risk factors cardiologists should know

Reviewing a patient's medical history can help care teams select the optimal post-TAVR oral anticoagulation strategy.

Sahil Parikh, MD, FSCAI, Director of Endovascular Services at New York-Presbyterian Columbia University Irving Medical Center, and Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons, explains there is scant clinical data on what the standard of care should be for pulmonary embolism, so it is up to clinicians to decide what is best for patients based on whether patients have mild to severe PE.

Pulmonary embolism treatments continue to evolve

There is still a lack of lack of standardized treatment protocols for pulmonary embolism. This is mainly due to limited data and a lack of reliable risk assessments, one specialist explained.

Displaying 89 - 96 of 854
Design by Adaptive Theme